ATS 2019 Virtual Final Program

BASIC • CLINICAL • TRANSLATIONAL TOMOKO BETSUYAKU, MD MEMORIAL SYMPOSIUM CME Credits Available: 2 A7 BREAKING THE PARADIGM: EARLY ORIGINS OF COPD Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Environmental, Occupational and Population Health; Pediatrics 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom D One (Level 3) Target Audience Patients; health care providers; pulmonary specialists; basic and translational scientists Objectives At the conclusion of this session, the participant will be able to: • define and understand the term “early COPD”; • identify the subjects at risk of developing COPD and thus targeting the early stages of the disease; • gain an overview of the current knowledge of the biological mechanisms underlying early COPD. The term “early COPD” is being used to indicate the presence of initial manifestations of COPD, such as airflow obstruction, in younger individuals. Recent evidence points toward other causes of early decline of lung function beyond cigarette smoking. This session will discuss the specific clinical and pathologic hallmarks of early COPD. Chairing: F.D. Martinez, MD, Tucson, AZ D.D. Sin, MD, Vancouver, Canada F. Polverino, MD, PhD, Tucson, AZ 9:15 A Patient's Perspective J. Rommes, W. Des Moines, IA 9:20 Does Early COPD Start at Birth? COPD Beyond Cigarette Smoke F.D. Martinez, MD, Tucson, AZ 9:39 Bronchopulmonary Dysplasia: An Emerging Culprit in Early COPD S.A. McGrath-Morrow, MD, Baltimore, MD 9:58 Pathobiology of Early COPD: An Incomplete Puzzle F. Polverino, MD, PhD, Tucson, AZ 10:17 Genomics of Early COPD: Where Do We Stand ? M.R. Faner, PhD, BSc, Barcelona, Spain 10:36 Early COPD and Late Mild COPD: Differences and Similarities S. Dharmage, MD, Melbourne, Australia 10:55 Microbiome and Host Response in Early COPD J. Hurst, MD, London, United Kingdom BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 MOC Points Available: 2 A8 CROSSING THE BORDER: MILDLY INCREASED PULMONARY ARTERY PRESSURE AND THE NEW DEFINITION OF PULMONARY HYPERTENSION Assembly on Pulmonary Circulation 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom C One-Two (Level 2) Target Audience All ATS attendees who are involved in patient care or research involving pulmonary hypertension Objectives At the conclusion of this session, the participant will be able to: • understand the normal limits of pulmonary artery pressure and rationale for thresholds used to diagnose pulmonary hypertension; • gain new findings about the epidemiology and natural history of mildly increased pulmonary artery pressure, both in the general population and specific patient subgroups; • improve the ability to diagnose and manage patients with mildly increased pulmonary artery pressures who fit the new definition of pulmonary hypertension. Emerging data indicates that having a mild increase in pulmonary artery pressure (below the threshold for diagnosis of pulmonary hypertension [PH]) is associated with a worse prognosis compared to individuals with a normal mean pulmonary artery pressure (mPAP), both in the general population and specific patient groups. Based on this data, the 2019 World Symposium on Pulmonary Hypertension recommended lowering the cut-off for PH diagnosis to a mPAP20mmHg. In this session, we will discuss this important new patient population who will now be defined as having PH, including epidemiology, natural history, and controversies regarding the changing definition and treatment decisions. Chairing: M.R. Lammi, MD, MSCR, New Orleans, LA E. Brittain, MD, Nashville, TN G. Kovacs, MD, Graz, Austria 9:15 Normal Limits of Pulmonary Artery Pressure and the Evolving Definition of Pulmonary Hypertension N.S. Hill, MD, Boston, MA 9:35 Epidemiology and Natural History of Patients with Mild Increases in Pulmonary Artery Pressure B.A. Maron, MD, Boston, MA 9:55 Case Study: Mildly Increased Pulmonary Artery Pressure in Scleroderma M.R. Lammi, MD, MSCR, New Orleans, LA 10:15 Case Study: Mildly Increased Pulmonary Artery Pressure in Sickle Cell Disease E.S. Klings, MD, Boston, MA ATS 2019 • Dallas, TX 28 SUNDAY • MAY 19